Sign in
4

Changes in Ownership

CytomX Therapeutics, Inc. Filed Acc 0001140361-17-045017

President and CEO sold 14,340 shares at $20.60 ($295,404)

  • President and CEO acquired 14,340 shares (option exercise)
  • President and CEO acquired 398 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
McCarthy Sean A. President and CEO 2017-11-30 Grant or award +398 $12.15 $4,834 4,643 D
McCarthy Sean A. President and CEO 2017-12-01 Option exercise +4,100 $0.95 $3,875 8,743 D
McCarthy Sean A. President and CEO 2017-12-01 Option exercise +10,240 $1.13 $11,611 18,983 D
McCarthy Sean A. President and CEO 2017-12-01 Sale −14,340 $20.60 $295,404 4,643 D
Derivatives
McCarthy Sean A. President and CEO 2017-12-01 Option exercise · Stock Option (right to buy) −4,100 115,193 D
McCarthy Sean A. President and CEO 2017-12-01 Option exercise · Stock Option (right to buy) −10,240 356,721 D
Open-market sales · 14,340 sh · avg $20.60 · $295,404
Loading xslF345X03/doc1.xml…